Skip to main content
SpringerLink
Log in
Book cover

Diagnosis and Management of Polycystic Ovary Syndrome pp 167–179Cite as

PCOS, Depression, and Alzheimer’s Disease

  • Chapter
  • First Online:

  • 1484 Accesses

Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized primarily by insulin resistance (IR), as well as hyperandrogenism and chronic anovulation [1]. PCOS is one of the most common endocrine disorders occurring in reproductive-aged women, with an estimated prevalence of between 4 and 6% [2]. Standard PCOS treatment entails insulin-sensitizing medications, such as biguanides (e.g., metformin) or peroxisome proliferator-activated receptors (PPAR) agonists (e.g., rosiglitazone, pioglitazone, and troglitazone) which generally results in improved metabolic and reproductive function in women with PCOS [3]. Depressive disorders are among the most common psychiatric diagnosis in America [4], and data indicate that women have double the lifetime risk of depression compared to men [4–7]. Mood disorders are the leading cause of disability among women aged 15–44 [8].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Dunaif A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401–419.

    PubMed  CAS  Google Scholar 

  2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333(13):853–861.

    PubMed  CAS  Google Scholar 

  3. Dunaif A. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81(9):3299–3306.

    PubMed  CAS  Google Scholar 

  4. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29(2–3):85–96.

    PubMed  CAS  Google Scholar 

  5. Bebbington P, Dunn G, Jenkins R, et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychol Med 1998;28(1):9–19.

    PubMed  CAS  Google Scholar 

  6. Nolen-Hoeksema S. Sex differences in depression. Stanford: Stanford University Press; 1990.

    Google Scholar 

  7. Weissman MM. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276(4):293–299.

    PubMed  CAS  Google Scholar 

  8. Murray CJL, Lopez AD. Alternative visions of the future: projecting mortality and disability, 1990–2020. In: Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston: Harvard University Press; 1996:325–395.

    Google Scholar 

  9. Rasgon NL, Rao RC, Hwang S, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003;74(3):299–304.

    PubMed  Google Scholar 

  10. Rasgon NL, Carter MS, Elman S, Bauer M, Love M, Korenman SG. Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. Curr Drug Targets Immune Endocr Metabol Disord 2002;2(1):97–102.

    PubMed  CAS  Google Scholar 

  11. Cooper B, Holmes C. Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. Age Ageing 1998;27:181–188.

    PubMed  CAS  Google Scholar 

  12. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer type. Am J Epidemiol 1985;121(3):414–421.

    PubMed  CAS  Google Scholar 

  13. Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ. Clinical risk factors for Alzheimer's disease: a population-based case-control study. Neurology 1991;41(9):1393–1397.

    PubMed  CAS  Google Scholar 

  14. Shalat SL, Seltzer B, Pidcock C, Baker EL. Risk factors for Alzheimer's disease: a case-control study. Neurology 1987;37(10):1630–1633.

    PubMed  CAS  Google Scholar 

  15. Speck CE, Kukull WA, Brenner DE, et al. History of depression as a risk factor for Alzheimer's disease. Epidemiology 1995;6(4):366–369.

    PubMed  CAS  Google Scholar 

  16. Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Saunders AM, Breitner JC. A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Biol Psychiatry 1997;41(8):851–856.

    PubMed  CAS  Google Scholar 

  17. Wetherell JL, Gatz M, Johansson B, Pedersen NL. History of depression and other psychiatric illness as risk factors for Alzheimer disease in a twin sample. Alzheimer Dis Assoc Disord 1999;13(1):47–52.

    PubMed  CAS  Google Scholar 

  18. Rasgon N, Jarvik GP, Jarvik L. Affective disorders and Alzheimer disease: a missing-link hypothesis. Am J Geriatr Psychiatry 2001;9(4):444–445.

    PubMed  CAS  Google Scholar 

  19. Rasgon NL, Jarvik L. Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. J Gerontol A Biol Sci Med Sci 2004;59(2):178–183.

    PubMed  Google Scholar 

  20. Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 2004;66(3):356–362.

    PubMed  CAS  Google Scholar 

  21. Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88(12):5801–5807.

    PubMed  CAS  Google Scholar 

  22. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 2007;87(6):1369–1376.

    PubMed  Google Scholar 

  23. Klipstein KG, Goldberg JF. Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study. J Affect Disord 2006;91:205–209.

    PubMed  Google Scholar 

  24. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593–602.

    PubMed  Google Scholar 

  25. Radloff L. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psych Meas 1977;1(3):385–401.

    Google Scholar 

  26. Baischer W, Koinig G, Hartmann B, Huber J, Langer G. Hypothalamic-pituitary-gonadal axis in depressed premenopausal women: elevated blood testosterone concentrations compared to normal controls. Psychoneuroendocrinology 1995;20(5):553–559.

    PubMed  CAS  Google Scholar 

  27. Shulman LH, DeRogatis L, Spielvogel R, Miller JL, Rose LI. Serum androgens and depression in women with facial hirsutism. J Am Acad Dermatol 1992;27(2 Pt 1):178–181.

    PubMed  CAS  Google Scholar 

  28. Weber B, Lewicka S, Deuschle M, Colla M, Heuser I. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 2000;25(8):765–771.

    PubMed  CAS  Google Scholar 

  29. Brantley PJ, Mehan DJJ, Thomas JL. The Beck Depression Inventory (BDI) and the Center for Epidemiologic Studies Depression scale (CES-D). In: Maruish MM, ed. Handbook of Psychological Assessment in Primary Care Settings. New Jersey: Lawrence Erlbaum Associates, Inc.; 1999.

    Google Scholar 

  30. Coyne JC, Schwenk TL. The relationship of distress to mood disturbance in primary care and psychiatric populations. J Consult Clin Psychol 1997;65(1):161–168.

    PubMed  CAS  Google Scholar 

  31. Myers JK, Weissman MM. Use of a self-report symptom scale to detect depression in a community sample. Am J Psychiatry 1980;137(9):1081–1084.

    PubMed  CAS  Google Scholar 

  32. Schulberg HC, Saul M, McClelland M, Ganguli M, Christy W, Frank R. Assessing depression in primary medical and psychiatric practices. Arch Gen Psychiatry 1985;42(12):1164–1170.

    PubMed  CAS  Google Scholar 

  33. Oddens BJ, den Tonkelaar I, Nieuwenhuyse H. Psychosocial experiences in women facing fertility problems—a comparative survey. Hum Reprod 1999;14(1):255–261.

    PubMed  CAS  Google Scholar 

  34. Williams KE, Marsh WK, Rasgon NL. Mood disorders and fertility in women: a critical review of the literature and implications for future research. Hum Reprod Update 2007;13(6):607–616.

    PubMed  Google Scholar 

  35. Eggers S, Kirchengast S. The polycystic ovary syndrome--a medical condition but also an important psychosocial problem. Coll Antropol 2001;25(2):673–685.

    PubMed  CAS  Google Scholar 

  36. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 2001;56(1):295–308.

    PubMed  CAS  Google Scholar 

  37. Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 1993;39:1–16.

    CAS  Google Scholar 

  38. Kitzinger C. The thief of womanhood: women's experience of polycystic ovarian syndrome. Soc Sci Med 2002;54(3): 349–361.

    PubMed  Google Scholar 

  39. Sills ES, Perloe M, Tucker M, Kaplan C, Genton M, Schattman G. Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports. BMC Womens Health 2001;1(1):3.

    PubMed  Google Scholar 

  40. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale--preliminary report. Psychopharmacol Bull 1973;9(1):13–28.

    PubMed  CAS  Google Scholar 

  41. Henrich G. Questions on life satisfaction (FLZ M): a short questionnaire for assessing subjective quality of life. Eur J Psychol Assess 2000;16(3):150–159.

    Google Scholar 

  42. Ware Jr, JE, Sherbourne CD. The MOS 36-Item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992;30(6):473–483.

    PubMed  Google Scholar 

  43. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305–315.

    PubMed  Google Scholar 

  44. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes 2002;26(7):883–896.

    CAS  Google Scholar 

  45. Flegal KL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288(14):1723–1727.

    PubMed  Google Scholar 

  46. Ciaraldi TP, Morales AJ, Hickman MG, Odom-Ford R, Olefsky JM, Yen SS. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 1997;82(5):1421–1425.

    PubMed  CAS  Google Scholar 

  47. Carmina E, Bucchieri S, Esposito A, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 2007;92(7):2500–2505.

    PubMed  CAS  Google Scholar 

  48. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001;16(6):1255–1260.

    PubMed  CAS  Google Scholar 

  49. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90(11):6014–6021.

    PubMed  CAS  Google Scholar 

  50. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006;113(10):1203–1209.

    PubMed  CAS  Google Scholar 

  51. Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol 1990;32(2):213–220.

    CAS  Google Scholar 

  52. Galtier-Dereure F, Pujol P, Dewailly D, Bringer J. Choice of stimulation in polycystic ovarian syndrome: the influence of obesity. Hum Reprod 1997;12 Suppl 1:88–96.

    PubMed  Google Scholar 

  53. Larsson B, Bengtsson C, Bjorntorp P, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? the study of men born in 1913 and the study of women, Goteborg, Sweden. Am J Epidemiol 1992;135(3):266–273.

    PubMed  CAS  Google Scholar 

  54. Ehrmann DA. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22(1):141–146.

    PubMed  CAS  Google Scholar 

  55. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type II diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999:165–169.

    Google Scholar 

  56. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65(3):499–507.

    PubMed  CAS  Google Scholar 

  57. Sharp PS, Kiddy DS, Reed MJ, Anyaoku V, Johnston DG, Franks S. Correlation of plasma insulin and insulin-like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome. Clin Endocrinol 1991;35(3):253–257.

    CAS  Google Scholar 

  58. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111(8):607–613.

    PubMed  CAS  Google Scholar 

  59. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001;16(9): 1995–1998.

    PubMed  CAS  Google Scholar 

  60. Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001;286(19):2421–2426.

    PubMed  CAS  Google Scholar 

  61. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of polycystic ovary syndrome. Hum Reprod 2000;15(4):785–789.

    PubMed  CAS  Google Scholar 

  62. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61(5):946–951.

    PubMed  CAS  Google Scholar 

  63. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005;96:399–404.

    PubMed  CAS  Google Scholar 

  64. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139(10):802–809.

    PubMed  Google Scholar 

  65. Carlson L, Bottiger L, Ahfeldt P. Risk factors for myocardial infarction in the Stockholm prospective study: a 14-year follow-up focusing on the role of plasma triglycerides and cholesterol. Acta Med Scand 1979;206:351–360.

    PubMed  CAS  Google Scholar 

  66. Castelli W, Garrison R, Wilson P, Abbott R, Kalonsdian S, Kannel W. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2385–2387.

    Google Scholar 

  67. Hokanson J, Austin M. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213–219.

    PubMed  CAS  Google Scholar 

  68. Miller G, Miller N. Plasma high-density-lipoprotein concentration and development of ischemic heart disease. Lancet 1975;1:16–19.

    PubMed  CAS  Google Scholar 

  69. Benson S, Janssen OE, Hahn S, et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav Immun 2008;22(2):177–184.

    PubMed  CAS  Google Scholar 

  70. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21(6):1426–1431.

    PubMed  CAS  Google Scholar 

  71. Cussons AJ, Stuckey BGA, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006;185(2):227–239.

    PubMed  CAS  Google Scholar 

  72. Orio F, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89(8):3696–3701.

    PubMed  CAS  Google Scholar 

  73. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103(10):1410–1415.

    PubMed  CAS  Google Scholar 

  74. Tiras MB, Yalcin R, Noyan V, et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 1999;14(8):1949–1952.

    PubMed  CAS  Google Scholar 

  75. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005;20(9):2409–2413.

    PubMed  Google Scholar 

  76. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored women's ischemia syndrome evaluation. J Clin Endocrinol Metab 2008;93(4):1276–1284.

    PubMed  CAS  Google Scholar 

  77. Solomon CG. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87(5):2013–2017.

    PubMed  CAS  Google Scholar 

  78. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.

    Google Scholar 

  79. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51(7):581–586.

    PubMed  CAS  Google Scholar 

  80. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 2000;52(5):595–600.

    CAS  Google Scholar 

  81. Battaglia C, Mancini F, Cianciosi A, et al. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. Obstet Gynecol 2008;111(2):385–395.

    PubMed  Google Scholar 

  82. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005;90(10):5711–5716.

    PubMed  CAS  Google Scholar 

  83. Aleman A, Bronk E, Kessels RPC, Koppeschaar HPF, van Honk J. A single administration of testosterone improves visuospatial ability in young women. Psychoneuroendocrinology 2004;29(5):612–617.

    PubMed  CAS  Google Scholar 

  84. Gouchie C, Kimura D. The relationship between testosterone levels and cognitive ability patterns. Psychoneuroendocrinology 1991;16(4):323–334.

    PubMed  CAS  Google Scholar 

  85. Hausmann M, Slabbekoorn D, Van Goozen SH, Cohen-Kettenis PT, Gunturkun O. Sex hormones affect spatial abilities during the menstrual cycle. Behav Neurosci 2000;114(6):1245.

    PubMed  CAS  Google Scholar 

  86. Moffat SD, Hampson E. A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference. Psychoneuroendocrinology 1996;21(3):323–337.

    PubMed  CAS  Google Scholar 

  87. Postma A, Meyer G, Tuiten A, van Honk J, Kessels RP, Thijssen J. Effects of testosterone administration on selective aspects of object-location memory in healthy young women. Psychoneuroendocrinology 2000;25(6):563–575.

    PubMed  CAS  Google Scholar 

  88. Shute VJ, Pellegrino JW, Hubert L, Reynolds RW. The relationship between androgen levels and human spatial abilities. Bull Psychonomic Soc 1983;21(6):465–468.

    CAS  Google Scholar 

  89. Hogervorst E. Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocrinology 2004;29(3):404–421.

    Google Scholar 

  90. Thilers PP, Macdonald SWS, Herlitz A. The association between endogenous free testosterone and cognitive performance: a population-based study in 35 to 90 year-old men and women. Psychoneuroendocrinology 2006;31(5):565–576.

    PubMed  CAS  Google Scholar 

  91. Schattmann L, Sherwin BB. Testosterone levels and cognitive functioning in women with polycystic ovary syndrome and in healthy young women. Hormones and Behavior 2007;51(5):587–596.

    PubMed  CAS  Google Scholar 

  92. Abbasi F, Brown B, Lamendola C, McLaughlin T, Reaven G. Relationship between obesity, insulin resistance, and coronary heart risk. J Am Coll Cardiol 2002;40:937–943.

    PubMed  CAS  Google Scholar 

  93. Schattmann L, Sherwin BB. Effects of the pharmacologic manipulation of testosterone on cognitive functioning in women with polycystic ovary syndrome: a randomized, placebo-controlled treatment study. Hormones and Behavior 2007;51(5): 579–586.

    PubMed  CAS  Google Scholar 

  94. Keettel WC, Bradbury JT, Stoddard FJ. Observations on the PCO syndrome. Am J Obstet Gynecol 1957;73:954–965.

    PubMed  CAS  Google Scholar 

  95. Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970;30:435–442.

    PubMed  CAS  Google Scholar 

  96. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF. Hyperfunction of the hypothalamic pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988;66:165–172.

    PubMed  CAS  Google Scholar 

  97. Barnard L, Balen AH, Ferriday D, Tiplady B, Dye L. Cognitive functioning in polycystic ovary syndrome. Psychoneuroendocrinology 2007;32(8–10):906–914.

    PubMed  CAS  Google Scholar 

  98. Potter GG, Steffens DC. Contribution of depression to cognitive impairment and dementia in older adults. Neurologist 2007;13(3):105–117.

    PubMed  Google Scholar 

  99. Osei K. Insulin resistance and systemic hypertension. Am J Cardiol 1999;84(1A):33 J–36 J.

    Google Scholar 

  100. Cannon-Spoor HE, Levy JA, Zubenko GS, et al. Effects of previous major depressive illness on cognition in Alzheimer disease patients. Am J Geriatr Psychiatry 2005;13(4):312–318.

    PubMed  Google Scholar 

  101. Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T. The course of geriatric depression with “reversible dementia": a controlled study. Am J Psychiatry 1993;150(11):1693–1699.

    PubMed  CAS  Google Scholar 

  102. Alexopoulos GS, Young RC, Meyers BS. Geriatric depression: age of onset and dementia. Biol Psychiatry 1993;34(3): 141–145.

    PubMed  CAS  Google Scholar 

  103. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40(11):1698–1707.

    PubMed  CAS  Google Scholar 

  104. Buntinx F, Kester A, Bergers J, Knottnerus JA. Is depression in elderly people followed by dementia? A retrospective cohort study based in general practice. Age Ageing 1996;25(3):231–233.

    PubMed  CAS  Google Scholar 

  105. Chen P, Ganguli M, Mulsant BH, DeKosky ST. The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Arch Gen Psychiatry 1999;56(3):261–266.

    PubMed  CAS  Google Scholar 

  106. Devanand DP, Sano M, Tang MX, et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996;53(2):175–182.

    PubMed  CAS  Google Scholar 

  107. Geerlings MI, Schoevers RA, Beekman AT, et al. Depression and risk of cognitive decline and Alzheimer's disease. Results of two prospective community-based studies in The Netherlands. Br J Psychiatry 2000;176:568–575.

    PubMed  CAS  Google Scholar 

  108. Reding M, Haycox J, Blass J. Depression in patients referred to a dementia clinic. A three-year prospective study. Arch Neurol 1985;42(9):894–896.

    PubMed  CAS  Google Scholar 

  109. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006;63(5):530–538.

    PubMed  Google Scholar 

  110. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001;178:200–206.

    PubMed  CAS  Google Scholar 

  111. Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE study. Arch Neurol 2003;60(5):753–759.

    PubMed  Google Scholar 

  112. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004;75(12):1662–1666.

    PubMed  CAS  Google Scholar 

  113. Kessing LV, Nilsson FM, Siersma V, Andersen PK. Increased risk of developing diabetes in depressive and bipolar disorders? J Psychiatr Res 2004;38(4):395–402.

    PubMed  Google Scholar 

  114. Palsson S, Aevarsson O, Skoog I. Depression, cerebral atrophy, cognitive performance and incidence of dementia. Population study of 85-year-olds. Br J Psychiatry 1999;174:249–253.

    PubMed  CAS  Google Scholar 

  115. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61(5):661–666.

    PubMed  Google Scholar 

  116. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995;38(9):1096–1102.

    PubMed  CAS  Google Scholar 

  117. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31(3):780–786.

    PubMed  CAS  Google Scholar 

  118. Kuusisto J, Koivisto K, Mykkanen L, et al. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension 1993;22(5):771–779.

    PubMed  CAS  Google Scholar 

  119. Leibson CL, O'Brien PC, Atkinson E, Palumbo PJ, Melton LJ. Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study. Am J Epidemiol 1997;146(1):12–22.

    PubMed  CAS  Google Scholar 

  120. Ott A, Stolk R, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999;53(9):1937–1942.

    PubMed  CAS  Google Scholar 

  121. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. Diabetes 2002;51(4):1256–1262.

    PubMed  CAS  Google Scholar 

  122. Stolk RP, Breteler MM, Ott A, et al. Insulin and cognitive function in an elderly population. The Rotterdam study. Diabetes Care 1997;20(5):792–795.

    PubMed  CAS  Google Scholar 

  123. Vanhanen M, Koivisto K, Kuusisto J, et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 1998;21(3):398–402.

    PubMed  CAS  Google Scholar 

  124. Beeri MS, Silverman JM, Davis KL, et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 2005;60(4):471–475.

    PubMed  Google Scholar 

  125. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes? J Alzheimers Dis 2005;7(1):63–80.

    PubMed  CAS  Google Scholar 

  126. Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997;315(7115): 1045–1049.

    PubMed  CAS  Google Scholar 

  127. Luchsinger JA, Tang M-X, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63(7): 1187–1192.

    PubMed  Google Scholar 

  128. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163(13):1524–1528.

    PubMed  Google Scholar 

  129. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999;52(5):971–975.

    PubMed  CAS  Google Scholar 

  130. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: the Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000;20(10):2255–2260.

    PubMed  CAS  Google Scholar 

  131. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004;53(4):495–499.

    PubMed  CAS  Google Scholar 

  132. Petersen KF, Dufour S, Savage DB, et al. Inaugural Article: The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci 2007;104(31):12587–12594.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, Stanford University, School of Medicine, Stanford, CA, USA

    Pascale G. Stemmle

Authors
  1. Pascale G. Stemmle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heather A. Kenna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalie L. Rasgon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pascale G. Stemmle .

Editor information

Editors and Affiliations

  1. The London Endocrine Clinic, 21 Wimpole Street, WIG 8GG, London, UK

    Nadir R. Farid

  2. University of Athens Medical School, Athens, Greece

    Evanthia Diamanti-Kandarakis

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Stemmle, P.G., Kenna, H.A., Rasgon, N.L. (2009). PCOS, Depression, and Alzheimer’s Disease. In: Farid, N.R., Diamanti-Kandarakis, E. (eds) Diagnosis and Management of Polycystic Ovary Syndrome. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09718-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09718-3_14

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09717-6

  • Online ISBN: 978-0-387-09718-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation